Literature DB >> 12150690

Babesiosis in humans: a treatment review.

Louis M Weiss1.   

Abstract

Human infections with Babesia species, in particular Babesia microti, are tick-borne illnesses that are being recognised with increased frequency. Coinfection with ehrlichiosis and Lyme disease is also being recognised as an important feature of these tick-borne illnesses. Despite the superficial resemblance of Babesia to malaria, these piroplasms do not respond to chloroquine or other similar drugs. However, the treatment of babesiosis using a clindamycin-quinine combination has been successful. Data in animal models and case-reports in humans have suggested that an atovaquone-azithromycin combination is also effective. This was confirmed in a recent prospective, open, randomised trial of clindamycin-quinine versus azithromycin-atovaquone. This paper reviews the literature on the treatment of human babesiosis and the animal models of these human pathogens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150690     DOI: 10.1517/14656566.3.8.1109

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  13 in total

Review 1.  Coinfections acquired from ixodes ticks.

Authors:  Stephen J Swanson; David Neitzel; Kurt D Reed; Edward A Belongia
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

2.  Novel diamidines with activity against Babesia divergens in vitro and Babesia microti in vivo.

Authors:  Angela Nehrbass-Stuedli; David Boykin; Richard R Tidwell; Reto Brun
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

3.  Potent antihematozoan activity of novel bisthiazolium drug T16: evidence for inhibition of phosphatidylcholine metabolism in erythrocytes infected with Babesia and Plasmodium spp.

Authors:  Eric Richier; Giancarlo A Biagini; Sharon Wein; Frederic Boudou; Patrick G Bray; Steve A Ward; Eric Precigout; Michèle Calas; Jean-François Dubremetz; Henri J Vial
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

Review 4.  The role of biocatalysis in the asymmetric synthesis of alkaloids - an update.

Authors:  Emmanuel Cigan; Bettina Eggbauer; Joerg H Schrittwieser; Wolfgang Kroutil
Journal:  RSC Adv       Date:  2021-08-20       Impact factor: 3.361

5.  Babesia microti: an unusual travel-related disease.

Authors:  Elodie Poisnel; Mikael Ebbo; Yael Berda-Haddad; Benoit Faucher; Emmanuelle Bernit; Bernard Carcy; Renaud Piarroux; Jean-Robert Harlé; Nicolas Schleinitz
Journal:  BMC Infect Dis       Date:  2013-02-22       Impact factor: 3.090

Review 6.  Current advances in detection and treatment of babesiosis.

Authors:  J Mosqueda; A Olvera-Ramirez; G Aguilar-Tipacamu; G J Canto
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

7.  Diagnosis and management of human babesiosis.

Authors:  Subhash Chandra Parija; Dinoop Kp; Hrudya Venugopal
Journal:  Trop Parasitol       Date:  2015 Jul-Dec

Review 8.  Hematologic manifestations of babesiosis.

Authors:  Tamer Akel; Neville Mobarakai
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-02-15       Impact factor: 3.944

9.  The effects of trans-chalcone and chalcone 4 hydrate on the growth of Babesia and Theileria.

Authors:  Gaber El-Saber Batiha; Amany Magdy Beshbishy; Dickson Stuart Tayebwa; Oluyomi Stephen Adeyemi; Hazem Shaheen; Naoaki Yokoyama; Ikuo Igarashi
Journal:  PLoS Negl Trop Dis       Date:  2019-05-24

Review 10.  Human babesiosis in Europe: what clinicians need to know.

Authors:  A Hildebrandt; J S Gray; K-P Hunfeld
Journal:  Infection       Date:  2013-10-09       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.